Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
523 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hepatitis C - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H2 2016, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape. Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 33, 19, 1, 56, 41 and 4 respectively for Similarly, the Universities portfolio in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 2, 1, 9 and 24 molecules, respectively for Hepatitis C. Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Hepatitis C Overview 8 Therapeutics Development 9 Hepatitis C - Therapeutics under Development by Companies 11 Hepatitis C - Therapeutics under Investigation by Universities/Institutes 18 Hepatitis C - Pipeline Products Glance 21 Hepatitis C - Products under Development by Companies 25 Hepatitis C - Products under Investigation by Universities/Institutes 36 Hepatitis C - Companies Involved in Therapeutics Development 38 Hepatitis C - Therapeutics Assessment 114 Drug Profiles 134 Hepatitis C - Dormant Projects 454 Hepatitis C - Discontinued Products 482 Hepatitis C - Product Development Milestones 490 Appendix 501
List of Tables
Number of Products under Development for Hepatitis C, H2 2016 30 Number of Products under Development for Hepatitis C - Comparative Analysis, H2 2016 31 Number of Products under Development by Companies, H2 2016 33 Number of Products under Development by Companies, H2 2016 (Contd..1) 34 Number of Products under Development by Companies, H2 2016 (Contd..2) 35 Number of Products under Development by Companies, H2 2016 (Contd..3) 36 Number of Products under Development by Companies, H2 2016 (Contd..4) 37 Number of Products under Development by Companies, H2 2016 (Contd..5) 38 Number of Products under Investigation by Universities/Institutes, H2 2016 40 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 41 Comparative Analysis by Late Stage Development, H2 2016 42 Comparative Analysis by Clinical Stage Development, H2 2016 43 Comparative Analysis by Early Stage Development, H2 2016 44 Comparative Analysis by Unknown Stage Development, H2 2016 45 Products under Development by Companies, H2 2016 46 Products under Development by Companies, H2 2016 (Contd..1) 47 Products under Development by Companies, H2 2016 (Contd..2) 48 Products under Development by Companies, H2 2016 (Contd..3) 49 Products under Development by Companies, H2 2016 (Contd..4) 50 Products under Development by Companies, H2 2016 (Contd..5) 51 Products under Development by Companies, H2 2016 (Contd..6) 52 Products under Development by Companies, H2 2016 (Contd..7) 53 Products under Development by Companies, H2 2016 (Contd..8) 54 Products under Development by Companies, H2 2016 (Contd..9) 55 Products under Development by Companies, H2 2016 (Contd..10) 56 Products under Investigation by Universities/Institutes, H2 2016 57 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 58 Hepatitis C - Pipeline by 3-V Biosciences, Inc., H2 2016 59 Hepatitis C - Pipeline by AbbVie Inc, H2 2016 60 Hepatitis C - Pipeline by AIMM Therapeutics B.V., H2 2016 61 Hepatitis C - Pipeline by Akshaya Bio Inc., H2 2016 62 Hepatitis C - Pipeline by Amarillo Biosciences, Inc., H2 2016 63 Hepatitis C - Pipeline by Amarna Therapeutics B.V., H2 2016 64 Hepatitis C - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016 65 Hepatitis C - Pipeline by Aviragen Therapeutics, Inc., H2 2016 66 Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016 67 Hepatitis C - Pipeline by Benitec Biopharma Limited, H2 2016 68 Hepatitis C - Pipeline by Beta Pharma, Inc., H2 2016 69 Hepatitis C - Pipeline by Biogenomics Limited, H2 2016 70 Hepatitis C - Pipeline by BioLineRx, Ltd., H2 2016 71 Hepatitis C - Pipeline by Bionor Pharma ASA, H2 2016 72 Hepatitis C - Pipeline by Biotest AG, H2 2016 73 Hepatitis C - Pipeline by Biotron Limited, H2 2016 74 Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H2 2016 75 Hepatitis C - Pipeline by Bolder Biotechnology, Inc., H2 2016 76 Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H2 2016 77 Hepatitis C - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 78 Hepatitis C - Pipeline by Cocrystal Pharma, Inc., H2 2016 79 Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc., H2 2016 80 Hepatitis C - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 81 Hepatitis C - Pipeline by DEKK-TEC, Inc., H2 2016 82 Hepatitis C - Pipeline by Delpor, Inc., H2 2016 83 Hepatitis C - Pipeline by Digna Biotech, S.L., H2 2016 84 Hepatitis C - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016 85 Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 86 Hepatitis C - Pipeline by Formune S.L., H2 2016 87 Hepatitis C - Pipeline by Genecode AS, H2 2016 88 Hepatitis C - Pipeline by GeneCure LLC, H2 2016 89 Hepatitis C - Pipeline by Gilead Sciences, Inc., H2 2016 90 Hepatitis C - Pipeline by GinkgoPharma Co. Ltd., H2 2016 91 Hepatitis C - Pipeline by GlaxoSmithKline Plc, H2 2016 92 Hepatitis C - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 93 Hepatitis C - Pipeline by HEC Pharm Co., Ltd., H2 2016 94 Hepatitis C - Pipeline by ImmunoBiology Limited, H2 2016 95 Hepatitis C - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 96 Hepatitis C - Pipeline by Integrated BioTherapeutics, Inc., H2 2016 97 Hepatitis C - Pipeline by JN-International Medical Corporation, H2 2016 98 Hepatitis C - Pipeline by Johnson & Johnson, H2 2016 99 Hepatitis C - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 100 Hepatitis C - Pipeline by Kineta, Inc., H2 2016 101 Hepatitis C - Pipeline by LG Life Science LTD., H2 2016 102 Hepatitis C - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 103 Hepatitis C - Pipeline by Medivir AB, H2 2016 104 Hepatitis C - Pipeline by Merck & Co., Inc., H2 2016 105 Hepatitis C - Pipeline by Microbio Co., Ltd., H2 2016 106 Hepatitis C - Pipeline by Microbiotix, Inc., H2 2016 107 Hepatitis C - Pipeline by MultiCell Technologies, Inc., H2 2016 108 Hepatitis C - Pipeline by NeuroVive Pharmaceutical AB, H2 2016 109 Hepatitis C - Pipeline by Novartis AG, H2 2016 110 Hepatitis C - Pipeline by NovaTarg Therapeutics, Inc, H2 2016 111 Hepatitis C - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 112 Hepatitis C - Pipeline by Pfenex Inc., H2 2016 113 Hepatitis C - Pipeline by Pfizer Inc., H2 2016 114 Hepatitis C - Pipeline by PharmaEssentia Corporation, H2 2016 115 Hepatitis C - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 116 Hepatitis C - Pipeline by Presidio Pharmaceuticals, Inc., H2 2016 117 Hepatitis C - Pipeline by Profectus BioSciences, Inc., H2 2016 118 Hepatitis C - Pipeline by Regulus Therapeutics Inc., H2 2016 119 Hepatitis C - Pipeline by REPLICor Inc., H2 2016 120 Hepatitis C - Pipeline by Rodos BioTarget GmbH, H2 2016 121 Hepatitis C - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 122 Hepatitis C - Pipeline by SomaGenics, Inc., H2 2016 123 Hepatitis C - Pipeline by Sorrento Therapeutics, Inc., H2 2016 124 Hepatitis C - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016 125 Hepatitis C - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 126 Hepatitis C - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016 127 Hepatitis C - Pipeline by TGV-Laboratories, H2 2016 128 Hepatitis C - Pipeline by Therapix Biosciences Ltd., H2 2016 129 Hepatitis C - Pipeline by Therapure Biopharma Inc., H2 2016 130 Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H2 2016 131 Hepatitis C - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 132 Hepatitis C - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016 133 Hepatitis C - Pipeline by Zylacta Corporation, H2 2016 134 Assessment by Monotherapy Products, H2 2016 135 Assessment by Combination Products, H2 2016 136 Number of Products by Stage and Target, H2 2016 138 Number of Products by Stage and Mechanism of Action, H2 2016 145 Number of Products by Stage and Route of Administration, H2 2016 152 Number of Products by Stage and Molecule Type, H2 2016 154 Hepatitis C - Dormant Projects, H2 2016 475 Hepatitis C - Dormant Projects (Contd..1), H2 2016 476 Hepatitis C - Dormant Projects (Contd..2), H2 2016 477 Hepatitis C - Dormant Projects (Contd..3), H2 2016 478 Hepatitis C - Dormant Projects (Contd..4), H2 2016 479 Hepatitis C - Dormant Projects (Contd..5), H2 2016 480 Hepatitis C - Dormant Projects (Contd..6), H2 2016 481 Hepatitis C - Dormant Projects (Contd..7), H2 2016 482 Hepatitis C - Dormant Projects (Contd..8), H2 2016 483 Hepatitis C - Dormant Projects (Contd..9), H2 2016 484 Hepatitis C - Dormant Projects (Contd..10), H2 2016 485 Hepatitis C - Dormant Projects (Contd..11), H2 2016 486 Hepatitis C - Dormant Projects (Contd..12), H2 2016 487 Hepatitis C - Dormant Projects (Contd..13), H2 2016 488 Hepatitis C - Dormant Projects (Contd..14), H2 2016 489 Hepatitis C - Dormant Projects (Contd..15), H2 2016 490 Hepatitis C - Dormant Projects (Contd..16), H2 2016 491 Hepatitis C - Dormant Projects (Contd..17), H2 2016 492 Hepatitis C - Dormant Projects (Contd..18), H2 2016 493 Hepatitis C - Dormant Projects (Contd..19), H2 2016 494 Hepatitis C - Dormant Projects (Contd..20), H2 2016 495 Hepatitis C - Dormant Projects (Contd..21), H2 2016 496 Hepatitis C - Dormant Projects (Contd..22), H2 2016 497 Hepatitis C - Dormant Projects (Contd..23), H2 2016 498 Hepatitis C - Dormant Projects (Contd..24), H2 2016 499 Hepatitis C - Dormant Projects (Contd..25), H2 2016 500 Hepatitis C - Dormant Projects (Contd..26), H2 2016 501 Hepatitis C - Dormant Projects (Contd..27), H2 2016 502 Hepatitis C - Discontinued Products, H2 2016 503 Hepatitis C - Discontinued Products (Contd..1), H2 2016 504 Hepatitis C - Discontinued Products (Contd..2), H2 2016 505 Hepatitis C - Discontinued Products (Contd..3), H2 2016 506 Hepatitis C - Discontinued Products (Contd..4), H2 2016 507 Hepatitis C - Discontinued Products (Contd..5), H2 2016 508 Hepatitis C - Discontinued Products (Contd..6), H2 2016 509 Hepatitis C - Discontinued Products (Contd..7), H2 2016 510
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.